- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07489495
Een klinische studie van Belzutifan (MK-6482) en Zanzalintinib bij mensen met niercelcarcinoom (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Een fase 3, gerandomiseerde, dubbelblinde studie van Belzutifan + Zanzalintinib versus Belzutifan + Placebo bij deelnemers met gevorderde RCC die zijn uitgeprogresseerd op of na zowel PD-1/L1- als VEGF-TKI-therapieën achtereenvolgens of in combinatie (LITESPARK-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).
A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Toll Free Number
- Telefoonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studie Locaties
-
-
-
CABA, Argentinië, C1426ANZ
- Werving
- Instituto Alexander Fleming ( Site 0252)
-
Contact:
- Study Coordinator
- Telefoonnummer: +541132218900
-
La Rioja, Argentinië, X5004BAL
- Werving
- Centro Oncológico Riojano Integral ( Site 0256)
-
Contact:
- Study Coordinator
- Telefoonnummer: +543804436443X108
-
San Juan, Argentinië, J5402BGA
- Werving
- COE (Centro Oncológico de Excelencia) ( Site 0259)
-
Contact:
- Study Coordinator
- Telefoonnummer: +54 2644229585
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentinië, C1426AHB
- Werving
- Centro Oncologico Korben ( Site 0254)
-
Contact:
- Study Coordinator
- Telefoonnummer: +541159507952
-
Ciudad de Buenos Aires, Buenos Aires, Argentinië, 1181
- Werving
- Hospital Italiano de Buenos Aires ( Site 0253)
-
Contact:
- Study Coordinator
- Telefoonnummer: +541149590200
-
Mar del Plata, Buenos Aires, Argentinië, B7600FZO
- Werving
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
-
Contact:
- Study Coordinator
- Telefoonnummer: +542234963224
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentinië, X5800ALB
- Werving
- Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
-
Contact:
- Study Coordinator
- Telefoonnummer: +543584620273
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentinië, S2000DSV
- Werving
- Sanatorio Parque ( Site 0251)
-
Contact:
- Study Coordinator
- Telefoonnummer: +5493416955611
-
Rosario, Santa Fe Province, Argentinië, S2000KZE
- Werving
- Instituto de Oncología de Rosario ( Site 0257)
-
Contact:
- Study Coordinator
- Telefoonnummer: +543414484830
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Australië, 2109
- Geschorst
- Macquarie University ( Site 2700)
-
-
Queensland
-
Woolloongabba, Queensland, Australië, 4102
- Geschorst
- Princess Alexandra Hospital ( Site 2703)
-
-
Victoria
-
Melbourne, Victoria, Australië, 3000
- Geschorst
- Peter MacCallum Cancer Centre ( Site 2702)
-
-
Western Australia
-
Murdoch, Western Australia, Australië, 6150
- Geschorst
- Fiona Stanley Hospital ( Site 2704)
-
-
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brazilië, 29055-450
- Werving
- CEDOES ( Site 0303)
-
Contact:
- Study Coordinator
- Telefoonnummer: +552721250202
-
-
Paraná
-
Curitiba, Paraná, Brazilië, 80510-130
- Werving
- Instituto do Câncer e Transplante de Curitiba ( Site 0300)
-
Contact:
- Study Coordinator
- Telefoonnummer: +55 41 99205-7755
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brazilië, 59062-000
- Werving
- Liga Norte Riograndense Contra o Câncer ( Site 0307)
-
Contact:
- Study Coordinator
- Telefoonnummer: +55 84 4009-5595
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brazilië, 14026-610
- Werving
- Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)
-
Contact:
- Study Coordinator
- Telefoonnummer: +55 16 3913-8181
-
São José do Rio Preto, São Paulo, Brazilië, 15090-000
- Werving
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
-
Contact:
- Study Coordinator
- Telefoonnummer: +55 17 3201-5054
-
-
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Werving
- The Ottawa Hospital Cancer Centre ( Site 0003)
-
Contact:
- Study Coordinator
- Telefoonnummer: 613-737-7700
-
-
-
-
Coquimbo Region
-
La Serena, Coquimbo Region, Chili, 1720430
- Werving
- IC La Serena Research ( Site 0405)
-
Contact:
- Study Coordinator
- Telefoonnummer: 56958646664
-
-
Los Lagos Region
-
Port Montt, Los Lagos Region, Chili, 5500243
- Werving
- Clínica Puerto Montt ( Site 0404)
-
Contact:
- Study Coordinator
- Telefoonnummer: +56985383586
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chili, 7500921
- Werving
- Fundacion Arturo Lopez Perez ( Site 0401)
-
Contact:
- Study Coordinator
- Telefoonnummer: 56224205098
-
Santiago, Region M. de Santiago, Chili, 8420383
- Werving
- Bradfordhill ( Site 0400)
-
Contact:
- Study Coordinator
- Telefoonnummer: 56229490970
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chili, 2520598
- Werving
- ONCOCENTRO APYS ( Site 0403)
-
Contact:
- Study Coordinator
- Telefoonnummer: 56323320850
-
-
-
-
Capital Region
-
Herlev, Capital Region, Denemarken, 2730
- Werving
- Herlev Hospital ( Site 1002)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00 45 38689191
-
-
Central Jutland
-
Aarhus, Central Jutland, Denemarken, 8200
- Werving
- Aarhus Universitetshospital, Skejby ( Site 1001)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4591167472
-
-
Region Syddanmark
-
Odense, Region Syddanmark, Denemarken, 5000
- Werving
- Odense Universitets Hospital ( Site 1000)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4566113333
-
-
-
-
-
Berlin, Duitsland, 10117
- Werving
- Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1312)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4930450515288
-
-
Bavaria
-
Augsburg, Bavaria, Duitsland, 86156
- Werving
- Universitaetsklinikum Augsburg ( Site 1316)
-
Contact:
- Study Coordinator
- Telefoonnummer: +498214002348
-
Munich, Bavaria, Duitsland, 81675
- Werving
- klinikum rechts der isar der technischen universität münchen ( Site 1315)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00498941402522
-
-
Thuringia
-
Jena, Thuringia, Duitsland, 07747
- Werving
- Universitätsklinikum Jena ( Site 1313)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4936419329970
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankrijk, 06189
- Werving
- Centre Antoine Lacassagne ( Site 1209)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33492031538
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, Frankrijk, 13003
- Werving
- Hopital Europeen Marseille ( Site 1216)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33413427427
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, Frankrijk, 31059
- Werving
- LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33531155050
-
-
Maine-et-Loire
-
Angers, Maine-et-Loire, Frankrijk, 49933
- Werving
- CHU Angers ( Site 1204)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33241354694
-
-
Pays de la Loire Region
-
Le Mans, Pays de la Loire Region, Frankrijk, 72000
- Werving
- Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33 243297908
-
Saint Priest En Jarez, Pays de la Loire Region, Frankrijk, 42271
- Werving
- CHU de Saint-Etienne ( Site 1202)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33477917082
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, Frankrijk, 94800
- Werving
- Gustave Roussy ( Site 1214)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33142114211
-
-
-
-
Attica
-
Athens, Attica, Griekenland, 185 47
- Werving
- Metropolitan Hospital ( Site 1402)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302104809667
-
Athens, Attica, Griekenland, 124 62
- Werving
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302105832549
-
Athens, Attica, Griekenland, 115 28
- Werving
- Alexandra General Hospital of Athens ( Site 1400)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302132162543
-
-
-
-
-
Haifa, Israël, 3109601
- Werving
- Rambam Health Care Campus ( Site 1600)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97247772688
-
Kfar Saba, Israël, 4428164
- Werving
- Meir Medical Center. ( Site 1603)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97297472555
-
Petah Tikva, Israël, 4941492
- Werving
- Rabin Medical Center ( Site 1602)
-
Contact:
- Study Coordinator
- Telefoonnummer: 97239378074
-
Ramat Gan, Israël, 5265601
- Werving
- Sheba Medical Center ( Site 1601)
-
Contact:
- Study Coordinator
- Telefoonnummer: 97235303030
-
-
-
-
-
Bari, Italië, 70124
- Werving
- Azienda Ospedaliera Policlinico di Bari ( Site 1802)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00390805593767
-
Bologna, Italië, 40138
- Werving
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1803)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390512142204
-
Milan, Italië, 20133
- Werving
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)
-
Contact:
- Study Coordinator
- Telefoonnummer: 02 2390 3028
-
Perugia, Italië, 06132
- Werving
- AO Santa Maria della Misericordia ( Site 1805)
-
Contact:
- Study Coordinator
- Telefoonnummer: +39 0755784188
-
Roma, Italië, 00168
- Werving
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00390630155202
-
Roma, Italië, 00144
- Werving
- Istituto Nazionale Tumori Regina Elena ( Site 1804)
-
Contact:
- Study Coordinator
- Telefoonnummer: +39 0652666919
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italië, 47014
- Werving
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1809)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390543739100
-
-
Milano
-
Rozzano, Milano, Italië, 20089
- Werving
- Istituto Clinico Humanitas ( Site 1808)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0282244061
-
-
Padova
-
Catselfranco Veneto, Padova, Italië, 31033
- Werving
- Istituto Oncologico Veneto IRCCS ( Site 1806)
-
Contact:
- Study Coordinator
- Telefoonnummer: +39 0423732336
-
-
Tuscany
-
Florence, Tuscany, Italië, 50134
- Werving
- Azienda Ospedaliera Universitaria Careggi ( Site 1807)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390557949648
-
-
-
-
Limburg
-
Maastricht, Limburg, Nederland, 6229 HX
- Werving
- Maastricht UMC+ ( Site 1901)
-
Contact:
- Study Coordinator
- Telefoonnummer: +31433877025
-
-
North Holland
-
Amsterdam, North Holland, Nederland, 1066 CX
- Werving
- Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)
-
Contact:
- Study Coordinator
- Telefoonnummer: +3120 512 9111
-
-
South Holland
-
Schiedam, South Holland, Nederland, 3118 JH
- Werving
- Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1903)
-
Contact:
- Study Coordinator
- Telefoonnummer: +31108931441
-
The Hague, South Holland, Nederland, 2545 AA
- Werving
- Haga Ziekenhuis locatie Leyweg ( Site 1906)
-
Contact:
- Study Coordinator
- Telefoonnummer: +3170 210 2143
-
-
-
-
Greater Poland Voivodeship
-
Skórzewo, Greater Poland Voivodeship, Polen, 60-185
- Werving
- AIDPORT Sp. z o.o. ( Site 2118)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48570783100
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-727
- Werving
- Pratia MCM Krakow ( Site 2115)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48122958160
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polen, 08-110
- Werving
- Mazowiecki Szpital Wojewódzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. ( Site 2102)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48256403300
-
Warsaw, Masovian Voivodeship, Polen, 02-172
- Werving
- MTZ Clinical Research Powered by Pratia ( Site 2107)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48225725959
-
Warsaw, Masovian Voivodeship, Polen, 02-781
- Werving
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 2100)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48225462331
-
-
Silesian Voivodeship
-
Gliwice, Silesian Voivodeship, Polen, 44-102
- Werving
- Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2106)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48322788237
-
-
-
-
-
Barcelona, Spanje, 08035
- Werving
- Hospital Universitari Vall d Hebron ( Site 2303)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34934894350
-
Las Palmas, Spanje, 35016
- Werving
- Hospital Insular de Gran Canaria ( Site 2308)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34928441738
-
Madrid, Spanje, 28041
- Werving
- Hospital Universitario 12 de Octubre ( Site 2300)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34913908339
-
Valencia, Spanje, 46009
- Werving
- Fundación Instituto Valenciano de Oncología ( Site 2307)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34961114229
-
-
Andalusia
-
Seville, Andalusia, Spanje, 41013
- Werving
- Hospital Universitario Virgen del Rocio ( Site 2306)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34955013068
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanje, 08908
- Werving
- Institut Català d'Oncologia - L'Hospitalet ( Site 2305)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34932607744
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanje, 28007
- Werving
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34914269393
-
-
-
-
-
Hradec Králové, Tsjechië, 500 05
- Werving
- Fakultni nemocnice Hradec Kralove ( Site 0902)
-
Contact:
- Study Coordinator
- Telefoonnummer: +420727854666
-
Olomouc, Tsjechië, 779 00
- Werving
- Fakultni nemocnice Olomouc ( Site 0901)
-
Contact:
- Study Coordinator
- Telefoonnummer: +420588445923
-
Prague, Tsjechië, 150 06
- Werving
- Fakultni nemocnice v Motole ( Site 0900)
-
Contact:
- Study Coordinator
- Telefoonnummer: +420734236410
-
Prague, Tsjechië, 128 08
- Werving
- Fakulti poliklinika ( Site 0906)
-
Contact:
- Study Coordinator
- Telefoonnummer: +420224966405
-
-
Brno-mesto
-
Brno, Brno-mesto, Tsjechië, 656 53
- Werving
- Masarykuv onkologicky ustav ( Site 0903)
-
Contact:
- Study Coordinator
- Telefoonnummer: +420543132216
-
-
Ostrava Mesto
-
Ostrava, Ostrava Mesto, Tsjechië, 708 52
- Werving
- Fakultni nemocnice Ostrava ( Site 0904)
-
Contact:
- Study Coordinator
- Telefoonnummer: +420597374322
-
-
-
-
-
Adana, Turkije (Türkiye), 01140
- Werving
- Adana Medical Park Seyhan Hastanesi ( Site 2505)
-
Contact:
- Study Coordinator
- Telefoonnummer: +905372688986
-
Ankara, Turkije (Türkiye), 06620
- Werving
- Ankara University Health Practice and Research Hospitals ( Site 2506)
-
Contact:
- Study Coordinator
- Telefoonnummer: +90 312 595 71 12
-
Edirne, Turkije (Türkiye), 22030
- Werving
- Trakya University Medical Faculty Hospital ( Site 2502)
-
Contact:
- Study Coordinator
- Telefoonnummer: +9005378528123
-
Istanbul, Turkije (Türkiye), 34010
- Werving
- Koc Universitesi Hastanesi ( Site 2501)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0090 850 250 8 250
-
Izmir, Turkije (Türkiye), 35080
- Werving
- Ege Universitesi Hastanesi ( Site 2503)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0 232 343 43 43
-
-
Ankara
-
Sıhhiye, Ankara, Turkije (Türkiye), 06230
- Werving
- Hacettepe Universite Hastaneleri ( Site 2500)
-
Contact:
- Study Coordinator
- Telefoonnummer: +905439340493
-
-
-
-
-
Birmingham, Verenigd Koninkrijk, B15 2GW
- Werving
- University Hospitals Birmingham NHS Foundation Trust ( Site 2610)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4407789651543
-
Cardiff, Verenigd Koninkrijk, CF14 2TL
- Werving
- Velindre Cancer Centre ( Site 2612)
-
Contact:
- Study Coordinator
- Telefoonnummer: +442920615888
-
Southampton, Verenigd Koninkrijk, SO16 6YD
- Werving
- University Hospital of Southampton ( Site 2606)
-
Contact:
- Study Coordinator
- Telefoonnummer: 023 8077 7222
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Verenigd Koninkrijk, CB2 0QQ
- Werving
- Addenbrookes Hospital ( Site 2605)
-
Contact:
- Study Coordinator
- Telefoonnummer: +441223805000
-
-
Edinburgh, City of
-
Edinburgh, Edinburgh, City of, Verenigd Koninkrijk, EH4 2XU
- Werving
- Western General Hospital ( Site 2608)
-
Contact:
- Study Coordinator
- Telefoonnummer: +441315371398
-
-
Glasgow City
-
Glasgow, Glasgow City, Verenigd Koninkrijk, G12 0YN
- Werving
- The Beatson West of Scotland Cancer Centre ( Site 2602)
-
Contact:
- Study Coordinator
- Telefoonnummer: +441413019916
-
-
Leicestershire
-
Leicester, Leicestershire, Verenigd Koninkrijk, LE1 5WW
- Werving
- Leicester Royal Infirmary ( Site 2604)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0300 303 1573
-
-
Manchester
-
Withington, Manchester, Verenigd Koninkrijk, M20 4BX
- Werving
- The Christie Hospital NHS Foundation Trust ( Site 2601)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0161 918 2546
-
-
-
-
Georgia
-
Marietta, Georgia, Verenigde Staten, 30060
- Werving
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)
-
Contact:
- Study Coordinator
- Telefoonnummer: 770-281-5124
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- Werving
- University of Louisville, James Graham Brown Cancer Center ( Site 0133)
-
Contact:
- Study Coordinator
- Telefoonnummer: 502-562-4673
-
Louisville, Kentucky, Verenigde Staten, 40207
- Werving
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)
-
Contact:
- Study Coordinator
- Telefoonnummer: 502-899-3366
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Beth Israel Deaconess Medical Center ( Site 0139)
-
Contact:
- Study Coordinator
- Telefoonnummer: 617-667-7000
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Dana Farber Cancer Institute ( Site 0135)
-
Contact:
- Study Coordinator
- Telefoonnummer: 617-632-3000
-
-
Michigan
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Werving
- The Cancer and Hematology Centers ( Site 0123)
-
Contact:
- Study Coordinator
- Telefoonnummer: 616-954-9800
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Washington University School of Medicine ( Site 0114)
-
Contact:
- Study Coordinator
- Telefoonnummer: 314-362-7355
-
-
New Jersey
-
Morristown, New Jersey, Verenigde Staten, 07960
- Werving
- Atlantic Health System Morristown Medical Center ( Site 0109)
-
Contact:
- Study Coordinator
- Telefoonnummer: 973-971-7960
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Werving
- Memorial Sloan Kettering Cancer Center ( Site 0126)
-
Contact:
- Study Coordinator
- Telefoonnummer: 347-798-9213
-
-
Tennessee
-
Germantown, Tennessee, Verenigde Staten, 38138
- Werving
- The West Clinic, P.C. ( Site 0115)
-
Contact:
- Study Coordinator
- Telefoonnummer: 901-683-0055
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- Werving
- UT Southwestern Medical Center ( Site 0119)
-
Contact:
- Study Coordinator
- Telefoonnummer: 214-648-3111
-
-
-
-
-
Seoul, Zuid -Korea, 05505
- Werving
- Asan Medical Center ( Site 2901)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82-2-3010-5977
-
Seoul, Zuid -Korea, 06351
- Werving
- Samsung Medical Center ( Site 2902)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82-2-3410-1767
-
Seoul, Zuid -Korea, 03722
- Werving
- Severance Hospital, Yonsei University Health System ( Site 2903)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82-2-2228-8138
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)
- Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
- Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1/Programmed Cell Death 1 Ligand 1 therapy
Exclusion Criteria:
For exclusion criteria: The main exclusion criteria include but are not limited to the following:
- Has any of the following: a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
- Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
- Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
- Has had major surgery within 8 weeks before randomization
- Has current pneumonitis/interstitial lung disease
- Has a history of human immunodeficiency virus infection
- Has Hepatitis B or Hepatitis C virus infection
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a history of solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Belzutifan + Zanzalintinib
Participants will receive 120 mg belzutifan orally and 60 mg zanzalintinib once daily for approximately 24 months. |
Tablet for oral administration.
Andere namen:
Tablet for oral administration.
Andere namen:
|
|
Actieve vergelijker: Belzutifan + Placebo
Participants will receive 120 mg belzutifan orally and zanzalintinib-matching placebo once daily for approximately 24 months. |
Tablet for oral administration.
Andere namen:
Zanzalintinib-matching placebo tablet for oral administration. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free Survival (PFS)
Tijdsspanne: Up to approximately 30 months
|
PFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. |
Up to approximately 30 months
|
|
Overall Survival (OS)
Tijdsspanne: Up to approximately 50 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 50 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 30 months
|
ORR is defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. |
Up to approximately 30 months
|
|
Duration of Response (DOR)
Tijdsspanne: Up to approximately 30 months
|
DOR is defined as the interval from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a best confirmed response of CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. |
Up to approximately 30 months
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Tijdsspanne: Up to approximately 25 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported. |
Up to approximately 25 months
|
|
Number of Participants who Discontinue Study Treatment Due to an AE
Tijdsspanne: Up to approximately 24 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 24 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Tijdsspanne: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Tijdsspanne: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Tijdsspanne: Baseline and up to approximately 25 months
|
The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported. |
Baseline and up to approximately 25 months
|
|
Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) (Items 1-9) Score
Tijdsspanne: Baseline and up to approximately 25 months
|
The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. |
Baseline and up to approximately 25 months
|
|
Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Tijdsspanne: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
Tijdsspanne: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score
Tijdsspanne: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in role functioning (Items 6 and 7). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in Disease Symptoms Using the FKSI-DRS (Items 1-9) Score
Tijdsspanne: Up to approximately 25 months
|
TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS score. The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Medical Director, Merck Sharp & Dohme LLC
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Urologische neoplasmata
- Carcinoom
- Nierneoplasmata
- Carcinoom, niercel
- Belzutifan
Andere studie-ID-nummers
- 6482-034
- U1111-1311-4692 (Register-ID: UTN)
- 2024-516993-31-00 (Register-ID: EU CT)
- LITESPARK-034 (Andere identificatie: MSD)
- MK-6482-034 (Andere identificatie: MSD)
- LS-034 (Andere identificatie: MSD)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .